An N-of-1 Study of Homeopathic Treatment of Fatigue in Patients Receiving Chemotherapy

Phase 1

Completed

• Conditions: Effects of Chemotherapy; Fatigue
• Interventions: Other: Unmedicated lactose/sucrose globule; Other: Homeopathic medicine

• Registration Number: NCT01983592
• Lead Sponsor: The Canadian College of Naturopathic Medicine

Brief Summary

Fatigue is frequently identified as one of the most troublesome symptoms in cancer patients and there are very few conventional therapies which can address the symptom of fatigue in patients who are undergoing cancer treatment.

This study will be testing whether the administration of a complementary therapy (individualized homeopathy) to a patient undergoing chemotherapy treatment is feasible and whether this treatment can lessen the fatigue symptoms of adults. The study will also test whether the n-of-1 study design is feasible in this population.

Detailed Description

This is an n-of-1 pilot trial of individualized homeopathic treatment of fatigue in a single adult who is undergoing any type of chemotherapy administered intermittently (i.e. not continuously). The participant will have a homeopathic consultation within 3 days of a round of chemotherapy ("treatment period") and will be administered either verum or placebo according to a binary randomization allocation sequence unknown to both the clinician and participant. During the subsequent treatment period the participant will be given the other allocation (verum or placebo). The following pairs of allocations will also be randomized with treatment continuing for as long as the participant is undergoing chemotherapy treatment.

Study Timeline

• Study First Submitted: 2013-11-07
• Study First Submitted QC: 2013-11-13
• Study First Posted: 2013-11-14
• Study Start: 2013-12
• Primary Completion: 2015-08
• Study Completion: 2015-09
• Status Verified: 2016-01
• Last Update Submitted: 2016-01-26
• Last Update Posted: 2016-01-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• Diagnosed with any type of cancer. Patient may have newly diagnosed, relapsed or a second malignant disease.
• Receiving any type of cytotoxic chemotherapy with 6 or more cycles post study enrollment administered intermittently every two or three weeks with no planned radiation treatment.
• Is experiencing fatigue due to the chemotherapy treatments. (or has a score of 2 or higher on the fatigue item of the Symptom Distress Scale)
• Above 18 years of age.
• Able to ingest medications in lactose/sucrose globule or liquid form.

Exclusion Criteria

• Previous history of allergy to the homeopathic products.
• Pregnant or lactating

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Unmedicated lactose/sucrose globule	Unmedicated lactose/sucrose globule	The placebo will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
Homeopathic medicine	Homeopathic medicine	The study medication will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.

Primary Outcome Measures

Name	Time	Method
Multidimensional Fatigue Inventory (MFI)	7 days	The Multidimensional Fatigue Inventory (MFI) is a 20-item, multi-dimensional, self-report instrument designed to measure fatigue. It covers the following 5 dimensions: 1) General Fatigue, 2) Physical Fatigue, 3) Mental Fatigue, 4) Reduced Motivation and 5) Reduced Activity.

Secondary Outcome Measures

Name	Time	Method
EORTC-QLQ-C30	7 days	The EORTC QLQ-C30 is a 30-item multi-dimensional questionnaire developed to assess the quality of life of cancer patients in the following four domains: functional scales; symptom scales; global quality of life; and single items.

Trial Locations

Locations (1)

Ottawa Integrative Cancer Centre; 🇨🇦 Ottawa, Ontario, Canada